Somatuline depot and Disseminated intravascular coagulation - a phase IV clinical study of FDA data

Summary:

Disseminated intravascular coagulation is reported only by a few people who take Somatuline Depot.

The phase IV clinical study analyzes which people take Somatuline depot and have Disseminated intravascular coagulation. It is created by eHealthMe based on reports of 3,998 people who have side effects while taking Somatuline depot from the FDA, and is updated regularly.

Phase IV trials are used to detect adverse drug outcomes and monitor drug effectiveness in the real world. With medical big data and AI algorithms, eHealthMe is running millions of phase IV trials and makes the results available to the public. Our original studies have been referenced on 600+ medical publications including The Lancet, Mayo Clinic Proceedings, and Nature.



On Sep, 27, 2022

3,998 people reported to have side effects when taking Somatuline depot.
Among them, 2 people (0.05%) have Disseminated intravascular coagulation.


What is Somatuline depot?

Somatuline depot has active ingredients of lanreotide acetate. It is often used in acromegaly. eHealthMe is studying from 4,024 Somatuline depot users for its effectiveness, alternative drugs and more.

What is Disseminated intravascular coagulation?

Disseminated intravascular coagulation (systemic activation of blood coagulation) is found to be associated with 1,829 drugs and 1,626 conditions by eHealthMe.

Number of Somatuline depot and Disseminated intravascular coagulation reports submitted per year:

Could Somatuline depot cause Disseminated intravascular coagulation?

Time on Somatuline depot when people have Disseminated intravascular coagulation *:

  • < 1 month: 100 %
  • 1 - 6 months: 0.0 %
  • 6 - 12 months: 0.0 %
  • 1 - 2 years: 0.0 %
  • 2 - 5 years: 0.0 %
  • 5 - 10 years: 0.0 %
  • 10+ years: 0.0 %

Gender of people who have Disseminated intravascular coagulation when taking Somatuline depot *:

  • female: 0.0 %
  • male: 100 %

Age of people who have Disseminated intravascular coagulation when taking Somatuline depot *:

  • 0-1: 0.0 %
  • 2-9: 0.0 %
  • 10-19: 0.0 %
  • 20-29: 0.0 %
  • 30-39: 0.0 %
  • 40-49: 0.0 %
  • 50-59: 0.0 %
  • 60+: 100 %

Common side effects people have besides Disseminated intravascular coagulation *:

  1. Septic Shock (shock due to blood infection): 1 person, 50.00%
  2. Muscle Haemorrhage (bleeding in muscle): 1 person, 50.00%
  3. Hepatic Failure (liver failure): 1 person, 50.00%
  4. Haemoglobin Decreased: 1 person, 50.00%

Common conditions people have *:

  1. Neuroendocrine Tumor: 2 people, 100.00%

* Approximation only. Some reports may have incomplete information.

Do you take Somatuline depot and have Disseminated intravascular coagulation?

Check whether Disseminated intravascular coagulation is associated with a drug or a condition

How to use the study?

You can discuss the study with your doctor, to ensure that all drug risks and benefits are fully discussed and understood.



Related studies

How severe was Disseminated intravascular coagulation and when was it recovered:

Expand to all the drugs that have ingredients of lanreotide acetate:

Alternative drugs to, pros and cons of Somatuline depot:

Common Somatuline depot side effects:

Browse all side effects of Somatuline depot:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Disseminated intravascular coagulation treatments and more:

COVID vaccines that are related to Disseminated intravascular coagulation:

Common drugs associated with Disseminated intravascular coagulation:

All the drugs that are associated with Disseminated intravascular coagulation:

Common conditions associated with Disseminated intravascular coagulation:

All the conditions that are associated with Disseminated intravascular coagulation:

How the study uses the data?

The study uses data from the FDA. It is based on lanreotide acetate (the active ingredients of Somatuline depot) and Somatuline depot (the brand name). Other drugs that have the same active ingredients (e.g. generic drugs) are not considered. Dosage of drugs is not considered in the study.

Who is eHealthMe?

With medical big data and proven AI algorithms, eHealthMe provides a platform for everyone to run phase IV clinical trials. We study millions of patients and 5,000 more each day. Results of our real-world drug study have been referenced on 600+ medical publications, including The Lancet, Mayo Clinic Proceedings, and Nature. Our analysis results are available to researchers, health care professionals, patients (testimonials), and software developers (open API).

WARNING, DISCLAIMER, USE FOR PUBLICATION

WARNING: Please DO NOT STOP MEDICATIONS without first consulting a physician since doing so could be hazardous to your health.

DISCLAIMER: All material available on eHealthMe.com is for informational purposes only, and is not a substitute for medical advice, diagnosis, or treatment provided by a qualified healthcare provider. All information is observation-only. Our phase IV clinical studies alone cannot establish cause-effect relationship. Different individuals may respond to medication in different ways. Every effort has been made to ensure that all information is accurate, up-to-date, and complete, but no guarantee is made to that effect. The use of the eHealthMe site and its content is at your own risk.

If you use this eHealthMe study on publication, please acknowledge it with a citation: study title, URL, accessed date.

Recent studies on eHealthMe: